東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Nanoparticles as a Vehicle for a Nov...

Pasa, Mariangela.

FindBook

Google Book

Amazon

博客來

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease./
作者:	Pasa, Mariangela.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2023,
面頁冊數:	70 p.
附註:	Source: Masters Abstracts International, Volume: 85-10.
Contained By:	Masters Abstracts International85-10.
標題:	Vaccines. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30878126
ISBN:	9798382050997

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.
Pasa, Mariangela.

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease. - Ann Arbor : ProQuest Dissertations & Theses, 2023 - 70 p.

Source: Masters Abstracts International, Volume: 85-10.

Thesis (M.Eng.)--Universidade do Porto (Portugal), 2023.

Alzheimer's disease (AD) is a neurodegenerative disease and the leading cause of dementia worldwide. To date, the therapies on the market for this disease are limited. This is due to, among many reasons, the difficulties in understanding completely the causes of the disease and the presence of the blood-brain barrier, a semipermeable border that prevents the entrance of solutes into the central nervous system. Therefore, the need to study new approaches for the targeted delivery of therapeutics to the brain.In recent years, nanoparticles able to transport molecules across the blood-brain barrier have gained attention and are a promising approach for the targeted delivery of therapeutics to the brain. This project intended to develop nanoparticles to encapsulate compounds for AD therapy. The nanoparticles were characterized through their size, polydispersity index, zeta potential and encapsulation efficiency. Different types of nanoparticles produced by different methods were studied: poly(lactic-co-glycolic acid) (PLGA) nanoparticles - with a focus on both oral and nose-to-brain delivery - and solid lipid nanoparticles. PLGA nanoparticles produced by the double emulsion method showed to have good and stable size and zeta potential over the time of the study; however, the encapsulation efficacy of a hydrophilic test compound in these particles was low. With the protocol to produce PLGA nanoparticles through a single emulsion, it was possible to obtain nanoparticles with a mean diameter of 239.4 nm, a polydispersity index of 0.108 and a zeta-potential of -19.3 mV. A mean diameter close to 200 nm increases the chance for the particles to cross the blood-brain barrier, so even if the size is close to the goal, further optimization will be required. Other PLGA nanoparticles surface-modified with chitosan intended for nose-to-brain delivery were produced, having a mean diameter of 199.1 nm, a polydispersity index of 0.1075 and a zeta-potential of 6.3 mV, being suitable for the application. Lastly, the protocol to produce solid lipid nanoparticles was optimized, and it was possible to achieve particles with an average size of 236.6 nm, a polydispersity index of 0.277 and a zeta potential of -21.1 mV.

ISBN: 9798382050997Subjects--Topical Terms:

684854
Vaccines.

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.
LDR:03366nmm a2200385 4500 001 2399749
005 20240916070001.5
006 m o d
007 cr#unu||||||||
008 251215s2023 ||||||||||||||||| ||eng d
020 $a 9798382050997
035 $a (MiAaPQ)AAI30878126
035 $a (MiAaPQ)Portugal10216150669
035 $a AAI30878126
040 $a MiAaPQ $c MiAaPQ
100 1 $a Pasa, Mariangela. $3 3769724
245 1 0 $a Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2023
300 $a 70 p.
500 $a Source: Masters Abstracts International, Volume: 85-10.
500 $a Advisor: Loureiro, Joana;Ramalho, Maria Joao.
502 $a Thesis (M.Eng.)--Universidade do Porto (Portugal), 2023.
520 $a Alzheimer's disease (AD) is a neurodegenerative disease and the leading cause of dementia worldwide. To date, the therapies on the market for this disease are limited. This is due to, among many reasons, the difficulties in understanding completely the causes of the disease and the presence of the blood-brain barrier, a semipermeable border that prevents the entrance of solutes into the central nervous system. Therefore, the need to study new approaches for the targeted delivery of therapeutics to the brain.In recent years, nanoparticles able to transport molecules across the blood-brain barrier have gained attention and are a promising approach for the targeted delivery of therapeutics to the brain. This project intended to develop nanoparticles to encapsulate compounds for AD therapy. The nanoparticles were characterized through their size, polydispersity index, zeta potential and encapsulation efficiency. Different types of nanoparticles produced by different methods were studied: poly(lactic-co-glycolic acid) (PLGA) nanoparticles - with a focus on both oral and nose-to-brain delivery - and solid lipid nanoparticles. PLGA nanoparticles produced by the double emulsion method showed to have good and stable size and zeta potential over the time of the study; however, the encapsulation efficacy of a hydrophilic test compound in these particles was low. With the protocol to produce PLGA nanoparticles through a single emulsion, it was possible to obtain nanoparticles with a mean diameter of 239.4 nm, a polydispersity index of 0.108 and a zeta-potential of -19.3 mV. A mean diameter close to 200 nm increases the chance for the particles to cross the blood-brain barrier, so even if the size is close to the goal, further optimization will be required. Other PLGA nanoparticles surface-modified with chitosan intended for nose-to-brain delivery were produced, having a mean diameter of 199.1 nm, a polydispersity index of 0.1075 and a zeta-potential of 6.3 mV, being suitable for the application. Lastly, the protocol to produce solid lipid nanoparticles was optimized, and it was possible to achieve particles with an average size of 236.6 nm, a polydispersity index of 0.277 and a zeta potential of -21.1 mV.
590 $a School code: 5896.
650 4 $a Vaccines. $3 684854
650 4 $a Blood-brain barrier. $3 812171
650 4 $a Toxicity. $3 3564836
650 4 $a Success. $3 518195
650 4 $a Drug delivery systems. $3 657987
650 4 $a Immunotherapy. $3 597370
650 4 $a Memory. $3 522110
650 4 $a Disease. $3 705846
650 4 $a Brain research. $3 3561789
650 4 $a Permeability. $3 915594
650 4 $a Dementia. $3 568139
650 4 $a Biomarkers. $3 2205735
650 4 $a Nervous system. $3 672432
650 4 $a Metabolism. $3 541349
650 4 $a Lipids. $3 558980
650 4 $a Cognitive ability. $3 3560491
650 4 $a Enzymes. $3 520899
650 4 $a Metabolites. $3 683644
650 4 $a Cognition & reasoning. $3 3556293
650 4 $a Drug dosages. $3 3557732
650 4 $a Bioavailability. $3 875104
650 4 $a Aging. $3 543123
650 4 $a Cognitive psychology. $3 523881
650 4 $a Immunology. $3 611031
650 4 $a Neurosciences. $3 588700
650 4 $a Pharmacology. $3 634543
650 4 $a Therapy. $3 3343697
650 4 $a Toxicology. $3 556884
690 $a 0493
690 $a 0633
690 $a 0982
690 $a 0317
690 $a 0419
690 $a 0212
690 $a 0383
710 2 $a Universidade do Porto (Portugal). $3 3348738
773 0 $t Masters Abstracts International $g 85-10.
790 $a 5896
791 $a M.Eng.
792 $a 2023
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30878126